benzyl N-[(1S)-1-{[(2S)-4-fluoro-3-oxobutan-2-yl]carbamoyl}-2-phenylethyl]carbamate

• ChemBase编号: 106523
• 分子式: C21H23FN2O4
• 平均质量: 386.4167232
• 单一同位素质量: 386.16418545
• SMILES: C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)C(=O)CF
• Canonical SMILES: FCC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)C
• InChI: InChI=1S/C21H23FN2O4/c1-15(19(25)13-22)23-20(26)18(12-16-8-4-2-5-9-16)24-21(27)28-14-17-10-6-3-7-11-17/h2-11,15,18H,12-14H2,1H3,(H,23,26)(H,24,27)/t15-,18-/m0/s1
• InChIKey: ASXVEBPEZMSPHB-YJBOKZPZSA-N

名称和登记号

名称

• IUPAC标准名: benzyl N-[(1S)-1-{[(2S)-4-fluoro-3-oxobutan-2-yl]carbamoyl}-2-phenylethyl]carbamate
• IUPAC传统名: benzyl N-[(1S)-1-{[(2S)-4-fluoro-3-oxobutan-2-yl]carbamoyl}-2-phenylethyl]carbamate
• 别名: Z-Phe-Ala-FMK; Z-FA-FMK; Z-Phe-Ala-Fluoromethylketone; Z-Phe-Ala fluoromethyl ketone

登记号

• CAS号: 96922-64-4
• MDL号: MFCD00883668
• PubChem SID: 162087690
• PubChem CID: 5311161

理论计算性质

• Acid pKa: 12.239405
• 质子受体: 3
• 质子供体: 2
• LogD (pH = 5.5): 3.107176
• LogD (pH = 7.4): 3.1071706
• Log P: 3.107176
• 摩尔折射率: 101.6549 cm^3
• 极化性: 39.398052 Å^3
• 极化表面积: 84.5 Å^2
• 可自由旋转的化学键: 10
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO or DMF: soluble20 mM
• 外观: white to off-white powder

安全信息

• 德国WGK号: 3
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• 保存温度: -20°C

产品相关信息

• 纯度: ≥90% (TLC)
• 运输包装: dry ice
• 线性分子式: C21H23N2O4F

详细说明

MP Biomedicals - 03FK029

A cell-permeable, irreversible cathepsin B inhibitor. Blocks LPS-induced production of IL-1a and IL-1b. Suitable as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position.

Sigma Aldrich - C1480

Application
An inhibitor of cysteine proteases, such as cathepsin B, which do not require a P1 Asp residue. It may be used as a negative control inhibitor for FMK P1 Asp caspase inhibitors.

参考文献

• Farber, A. et al., J. Vasc. Surg., 30(4):752 (1999).
• Schotte, P., et al. 2001. J. Biol. Chem. 276, 21153.
• Guo, H., et al. 1998. Exp. Cell Res. 245, 57.
• Rosenthal, P.J., et al. 1993. J. Clin. Invest. 91, 1057.
• Ahmed, N.K., et al. 1992. Biochem. Pharmacol. 44, 1201.
• Rauber, P., et al. 1986. Biochem. J. 239, 633.
• Shaw, E., et al. 1986. Biomed. Biochim. Acta 45, 1397.
• Rasnick, D. 1985. Anal. Biochem. 149, 461.